Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123-CD16 bispecific antibody-modified NK cells
- Development stage
- Phase 1
- Lead developer
- Chinese PLA General Hospital
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD123-CD16 bispecific antibody-modified NK cells are donor-derived natural killer (NK) cells that have been modified using a bispecific antibody targeting both CD123 on tumor cells and CD16 on NK cells. The mechanism leverages the bispecific antibody to bind CD123 (interleukin-3 receptor α chain) present on acute myeloid leukemia (AML) cells and CD16 (Fcγ receptor IIIa) on NK cells, bringing them into close proximity to induce targeted cytotoxicity through antibody-dependent cell-mediated cytotoxicity (ADCC). This investigational immunotherapy aims to harness and enhance the innate cytotoxic potential of NK cells against CD123-positive hematological malignancies, primarily relapsed or refractory acute myeloid leukemia (AML). The therapy is currently being tested in early-phase clinical trials and involves ex vivo modification and expansion of NK cells prior to infusion into patients[1][4][6].
- Other names
- CD123-CD16-NK cellsCD-123-CD16-NK cellsCD 123-CD16-NK cellsdonor-derived CD123-CD16 bispecific antibody-modified NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on CD123-CD16 bispecific antibody-modified NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123-CD16 bispecific antibody-modified NK cells.